key: cord-0951431-1qgnjv6s authors: Jones, Ian D. title: The impact of Covid‐19 on cardiovascular health date: 2022-04-06 journal: Nurs Crit Care DOI: 10.1111/nicc.12756 sha: 85a5773d0260297f9fcaa78f073979e62724b17b doc_id: 951431 cord_uid: 1qgnjv6s nan When the editors asked me to produce an editorial that focussed on the current cardiac-related issues in intensive care nursing, I pondered for some time about the content of the paper and how I might move the debate beyond Coronavirus Disease 2019 . Unfortunately, whilst many, if not most of the critical care workforce is physically, psychologically and emotionally tired of the effects of the pandemic, viral mutation, an unwillingness or inability for some to receive the vaccines mean that we are likely to see Covid-19 patients in critical care units for some time. Moreover, the number of people attending hospital with Acute Coronary Syndrome (ACS), 1-5 heart failure, 6 arrhythmia 7 and those requiring emergency cardiac surgery 8 dramatically reduced during the pandemic. Consequently, it is likely that some of these patients will suffer the long-term effects of missed treatment and require critical care nursing at some point in the future. It, therefore, still seems appropriate to consider the cardiac ramifications of Covid-19 and its implications for the critical care nurse. Covid-19 is caused by the severe acute respiratory syndrome corona- Acute myocardial injury, evidenced by raised Troponin levels, is believed to occur in 9-40% 20 of hospitalized patients and has been shown to be a negative prognostic indicator, [21] [22] [23] including increased admission to intensive care and death. 24, 25 The mechanism in which SARS-Cov-2 induces myocardial injury is unclear but may include the alteration of the ACE2 signalling pathways, 26,27 the effect of a cytokine storm associated with systemic inflammation 22.23 and/or additional myocardial workload resulting from respiratory failure and hypoxia. Irrespective of the underlying pathology, myocardial injury leads to increased risk of cardiovascular complications, including, myocarditis, arrhythmia, heart failure and ACS. 28 Early case reports suggested that myocarditis was a common complication of Covid-19. 29, 30 These results were unsurprising given that in one Canadian study 35% of patients who died during the 2002 SARS outbreak were found to have evidence of the virus within their hearts. 31 However, the task force for the management of Covid-19 of the European Society of Cardiology 28 have suggested that a definitive diagnosis of myocarditis can only be made following examination of endomyocardial biopsies and, as such, the evidence that myocarditis is a common complication of Covid-19 is yet to be convincingly demonstrated. Tachy and brady arrhythmias are common in patients with Covid-19. One study from China reported 16.7% of hospitalized patients experienced arrhythmias, which increased to 44% in those requiring intensive care management. However, the authors failed to report the type of arrhythmia. More recent studies 32, 33 have reported arrhythmia prevalence of between 7 and 25% with atrial fibrillation accounting for 5-15% of all reported arrhythmia. Both papers report a correlation between arrhythmia and disease severity with Peltzer and colleagues 32 also reporting a correlation between arrhythmia and 30-day mortality. Whilst arrhythmia prevalence is not uncommon in hospitalized Covid-19 patients, this frequency increases in those requiring intensive care. In one observational study of 113 intensive care patients in Germany, 34 Heart failure-related admissions reduced significantly during the height of the Covid-19 pandemic in 2020 36 with patients presenting with more advanced signs of decompensation 37 and an increased level of brain natriuretic peptide both of which are associated with higher mortality. 38 Some have speculated that patients may have delayed seeking help for fear of contracting Covid-19; however, in our recent work, 39 we found that patients with CVD delayed seeking help during the pandemic as they were often unable to interpret their symptoms. When faced with public health messaging, which suggested that people should only attend hospital if the situation was life-threatening, they chose to stay at home. The prevalence of chronic heart failure (CHF) as a comorbid condition in the Covid-19 population has been reported as 3-21% 40 with CHF associated with an increased risk of mortality 41, 42 and need for mechanical ventilation. 43 In addition to those that present with CHF, between 2 and 23% of patients will develop acute heart failure because of the infection. The large variation in prevalence between studies is probably related to the diverse methods of data collection rather than variations in populations. For example, Zhou et al. 21 report prevalence of heart failure as an outcome but do not record the number of patients with CHF on admission. It is therefore feasible that some of the 23% of patients reported as suffering from heart failure in this study were suffering from chronic heart failure and that increased metabolic demand exposed subclinical heart failure. It is clear from the combined data that up to one-fifth of Covid-19 patients will experience heart failure during their illness and the presence of heart failure increases a patient's need for critical care management. Whilst the most severe cases will require mechanical ventilation and system support to maintain organ perfusion, it is essential that fundamental heart failure treatment is included in their management plan. Whilst during the early days of the pandemic, there was a belief that ACE inhibitors might lead to up-regulation of the ACE2 receptors, therefore, increasing risk, there is no evidence that this occurs, and ACE inhibitors along with other evidence-based therapies should form part of routine heart failure management as per European Society of cardiology guidelines. 44 Adults with congenital heart disease (CHD) are assumed to be at greater risk from Covid-19 due to residual haemodynamic lesions such as valve disorders, reduced left ventricular function and arrhythmia. 46 However, recent evidence obtained from 58 CHD centres, including 1044 Covid-19 positive patients suggests that CHD mortality rates are no greater than the wider population. 47 Nevertheless, it might be unwise to treat those with CHD as a homogenous group with evidence that those with worse physiological state, such as cyanosis and pulmonary hypertension, renal insufficiency and previous heart failure, are at greater risk. 47 The latest European guidelines 21 suggest early admission to hospital and an intensive care management plan to be discussed with a CHD specialist in all those except the lowest risk. Patients with CVD are at greater risk of dying of Covid-19 and are more likely to require intensive care nursing. Critically ill patients with Covid-19 often suffer cardiovascular complications that require immediate and ongoing management. As the incidence of Covid-19 increases once more, it is essential that nurses recognize the influence of comorbid heart disease on clinical outcome so that we can prevent or manage their potential complications and reduce subsequent morbidity and mortality. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en Espana The COVID-19 pandemic and the incidence of acute myocardial infarction Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment_elevation myocardial infarction care in Hong Kong Decreases in acute heart failure hospitalizations during COVID-19 Helios hospitals G. emergency hospital admissions and interventional treatments for heart failure and cardiac arrhythmias in Germany during the COVID-19 outbreak: insights from the German-wide Helios hospital network The impact of the COVID-19 pandemic on cardiac surgery and transplant services in Ireland's national centre An interactive web-based dashboard to track COVID-19 in real time Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS) Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a wholepopulation study Features of severe COVID-19: a systematic review and meta-analysis Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and metaanalysis Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Coronaviruses and the cardiovascular system: acute and long-term implications Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China The task force for the management of COVID-19 of the European Society of Cardiology, European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis The variety of cardiovascular presentations of COVID-19 Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS Arrhythmic complications of patients hospitalized with COVID-19: incidence, risk factors, and outcomes Cardiac arrhythmias amongst hospitalised coronavirus 2019 (COVID-19) patients: prevalence, characterisation, and clinical algorithm to classify arrhythmic risk Cardiac arrhythmias in patients with COVID-19: lessons from 2300 telemetric monitoring days on the intensive care unit Cardiac arrhythmias in critically ill patients with coronavirus disease 2019: a retrospective population-based cohort study The impact of COVID-19 on heart failure hospitalization and management: report from a heart failure unit in London during the peak of the pandemic COVID-19 and cardiac arrhythmias Meta-analysis of cardiovascular events and related biomarkers comparing survivors versus nonsurvivors in patients with COVID-19 Should I stay or should I go? An exploration of the decision-making behaviour of acute cardiac patients during the Covid-19 pandemic Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study The case fatality rate in COVID-19 patients with cardiovascular disease: global health challenge and paradigm in the current pandemic Prognostic impact of prior heart failure in patients hospitalized with COVID-19 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC focus seminar Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease COVID-19 in adults with congenital heart disease